Home/Protocols/PT-141
Protocol Reference
Human trial data

PT-141 protocol

PT-141 / bremelanotide (melanocortin receptor agonist). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
Sexual & Cosmetic
Common vials
10 mg
Half-life
~2.7 hours
Route in the literature
Subcutaneous
Evidence level
Human trial data

How PT-141 works

A melanocortin-receptor agonist derived from the alpha-MSH analog melanotan II. It acts centrally on MC4 receptors rather than on the vascular system, which is what distinguishes it mechanistically from PDE5 inhibitors.

PT-141 dosing schedule

From the approved label. Bremelanotide is FDA-approved as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Note it is an as-needed product with an explicit frequency ceiling — that limit is part of the protocol, not an afterthought.

PhaseAmountFrequencyNotes
Approved use1.75 mgAs needed, subcutaneous, at least 45 minutes before anticipated activityThe single approved amount.
Labelled maximum1 dose per 24 hoursNo more than 8 doses per monthThe frequency ceiling is part of the approved labelling.

Study length: As-needed use rather than a course. The label caps use at one dose in 24 hours and no more than eight per month.

Source for this schedule: Bremelanotide (Vyleesi) prescribing information, HSDD indication. This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for PT-141: 10 mg.

Open the PT-141 calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Reported effects

  • Nausea is the most frequently reported adverse event in the trials — common enough that the label addresses it directly.
  • Transient blood-pressure increase and heart-rate decrease occur after each dose; the label contraindicates use in uncontrolled hypertension or known cardiovascular disease.
  • Focal hyperpigmentation was reported with repeated use, consistent with melanocortin activity.

Sourcing PT-141

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

PT-141 at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

Sources and further reading

For laboratory research use only. This page documents what the published literature reports about PT-141. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →